Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q2 2021 · 10-Q
Revenue$78.85M$78.85M+90.4% vs Q2 2020 Net Income$30.73M$30.73M+39.1% vs Q2 2020 EPS Diluted$1.79$1.79+35.6% vs Q2 2020 Operating Income$45,739,000+544.2% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$18,987,000— Margins · derivedOperating margin58.0%+40.9 pt vs Q2 2020
Net margin39.0%−14.4 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 3, 2021 · 34 d after period end